About Our Co-founding Stealth Mode Biotech
The Problem we are addressing
The escalating complexity of modern drugs poses a dual challenge. Not only does it strain the research community to ensure accessibility & affordability for the general public (beyond the elite sector), but it also introduces intricate features such as complex architectures, multiple ring systems, stereo-centers, and macrocyclic rings in next-generation drugs. Addressing this complexity requires the development of novel, practical, and cost-effective methods applicable both in R&D proof of concept and manufacturing. This ongoing challenge hinders generic research programs. Our biotech aims to tackle these issues through innovative, carefully architected approaches. The development of novel methods, potentially protected by intellectual property (IP), positions us uniquely to bring these complex drugs onto the generic path with a commanding advantage.
Our Solution
Our Stealth Mode Biotech stands at the forefront of revolutionizing healthcare accessibility through innovation in Process Chemistry & Manufacturing, focusing on Complex Generics. Our primary goal is to create generic versions of challenging drugs across critical disease areas, ensuring affordability for all. We're committed to achieving this objective through the application of highly innovative and modern skill sets. Our approach involves practical and scalable organic synthesis, coupled with stereoselective organic synthesis, employing clever and cost-effective methodologies not comprehensively explored until now.
Our USP's
At the heart of Stealth Mode Biotech lies an unparalleled blend of cutting-edge scientific and managerial leadership. Among our five co-founding leaders, four possess an exceptional track record in modern organic synthesis, stereoselective organic synthesis, and process chemistry for complex molecules—both natural and non-natural. Complementing this scientific prowess, our fifth co-founding leader brings a global managerial perspective, combining enriched experiences in engineering and business development.
For our inaugural programs, we've meticulously curated a selection of 20 drugs and drug candidates, which represent a strategic choice, demonstrating our foresight and confidence in building a robust Intellectual Property (IP) portfolio through novel and innovative chemical approaches.
Our Co-founders
Prof. K C Nicolaou, PhD
Prof. K C Nicolaou, PhD
Prof. K C Nicolaou, PhD
Harry C. and Olga K. Wiess Chair of Chemistry Rice University ; Former Professor, Scripps Research
Posses more than 50 years experience in the synthesis of complex small molecules / natural products and related compounds; Trained more than 800 students and Post doctoral fellows; Published more than 850 articles; A leading authority in the
Harry C. and Olga K. Wiess Chair of Chemistry Rice University ; Former Professor, Scripps Research
Posses more than 50 years experience in the synthesis of complex small molecules / natural products and related compounds; Trained more than 800 students and Post doctoral fellows; Published more than 850 articles; A leading authority in the world in developing clever and practical approaches to complex small molecules
Prof. Javed Iqbal, PhD
Prof. K C Nicolaou, PhD
Prof. K C Nicolaou, PhD
Former Chemistry Professor, IIT Kanpur ;
Former Director, Dr.Reddy’s Inst of Life Sciences (DRILS)
A Chemical Biologist having worked in Academia and Pharmaceutical industry over the last 38 years. Have guided 40 PhD and Masters students and have published more than 200 research publications and patents; Consultant/mentor to several Pharmaceuticals companies.
Prabhat Arya, PhD
Prof. K C Nicolaou, PhD
Jagadeesh Ganaparthi, MS(Chem) ; MBA
Former Distinguished Research Professor, DRILS
Former Adjunct Professor, Biochem, McGill,
Co-founder of Biotech Companies
A cutting-edge leadership of more than 40 years in complex small molecule / natural product-inspired compound synthesis; stereoselective organic synthesis; Published extensively with >120 articles; Delivered >170 invite
Former Distinguished Research Professor, DRILS
Former Adjunct Professor, Biochem, McGill,
Co-founder of Biotech Companies
A cutting-edge leadership of more than 40 years in complex small molecule / natural product-inspired compound synthesis; stereoselective organic synthesis; Published extensively with >120 articles; Delivered >170 invited lectures; Trained >80 fellows; Passionate about connecting “scientific research to the business world” in making affordable medicines
Jagadeesh Ganaparthi, MS(Chem) ; MBA
Jagadeesh Ganaparthi, MS(Chem) ; MBA
Jagadeesh Ganaparthi, MS(Chem) ; MBA
An illustrious career spanning more that 25 years across diverse corporate landscapes & Continents
A versatile global leader having rich all-round experience in various sectors spanning Operations, Strategy, Business Development, Conceptualization, and execution of global projects etc., in both established and startup companies. Worked wi
An illustrious career spanning more that 25 years across diverse corporate landscapes & Continents
A versatile global leader having rich all-round experience in various sectors spanning Operations, Strategy, Business Development, Conceptualization, and execution of global projects etc., in both established and startup companies. Worked with diverse stakeholders across the United States, Asia, Europe, and the Middle East, cultivating a strong global network
K Bhaskar, PhD MBA
Jagadeesh Ganaparthi, MS(Chem) ; MBA
K Bhaskar, PhD MBA
Founder, Syngreen Life Sciences; Former Group leader & Delivery Head Centre for Process Research & Development, DRILS
Having more than 25 years of experience in developing programs related to the IP-based process synthesis of several generic & complex generic drugs and numerous APIs; Extensive experience in leading end to end novel produc
Founder, Syngreen Life Sciences; Former Group leader & Delivery Head Centre for Process Research & Development, DRILS
Having more than 25 years of experience in developing programs related to the IP-based process synthesis of several generic & complex generic drugs and numerous APIs; Extensive experience in leading end to end novel product development and the timely delivery to the market ; Played a leadership role in technical, strategic and operational support across the pharmaceutical value chain, especially in R&D in APIs